Gilead Sciences Inc. posted fourth-quarter earnings that missed expectations as the biotechnology giant fends off threats to its best-selling drugs and prepares for a new CEO to take the reins.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,